- Home
- SLRC vs ELVN Comparison
SLRC vs ELVN Comparison
Compare SLRC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRC
- ELVN
- Stock Information
- Founded
- SLRC 2007
- ELVN 2016
- Country
- SLRC United States
- ELVN United States
- Employees
- SLRC N/A
- ELVN N/A
- Industry
- SLRC Finance/Investors Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- SLRC Finance
- ELVN Health Care
- Exchange
- SLRC Nasdaq
- ELVN Nasdaq
- Market Cap
- SLRC 889.2M
- ELVN 927.8M
- IPO Year
- SLRC 2010
- ELVN 2020
- Fundamental
- Price
- SLRC $16.18
- ELVN $21.30
- Analyst Decision
- SLRC Hold
- ELVN Strong Buy
- Analyst Count
- SLRC 6
- ELVN 5
- Target Price
- SLRC $15.79
- ELVN $39.60
- AVG Volume (30 Days)
- SLRC 127.3K
- ELVN 594.3K
- Earning Date
- SLRC 08-06-2025
- ELVN 08-12-2025
- Dividend Yield
- SLRC 10.11%
- ELVN N/A
- EPS Growth
- SLRC N/A
- ELVN N/A
- EPS
- SLRC 1.61
- ELVN N/A
- Revenue
- SLRC $227,510,000.00
- ELVN N/A
- Revenue This Year
- SLRC N/A
- ELVN N/A
- Revenue Next Year
- SLRC N/A
- ELVN N/A
- P/E Ratio
- SLRC $10.08
- ELVN N/A
- Revenue Growth
- SLRC N/A
- ELVN N/A
- 52 Week Low
- SLRC $13.64
- ELVN $13.30
- 52 Week High
- SLRC $17.94
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- SLRC 42.29
- ELVN 55.53
- Support Level
- SLRC $16.04
- ELVN $18.53
- Resistance Level
- SLRC $16.60
- ELVN $24.11
- Average True Range (ATR)
- SLRC 0.21
- ELVN 1.96
- MACD
- SLRC -0.11
- ELVN 0.15
- Stochastic Oscillator
- SLRC 12.07
- ELVN 55.68
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.